CLICK HERE for event replay.
We hosted a conversation with Kyle Detwiler, the Clever Leaves CEO, on Thursday, December 3rd. Clever Leaves is expected to close its merger with Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA) in Q4 under the new ticker "CLVR." It's anticipated that CLVR will be listed on the NASDAQ.
Clever Leaves is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids with its primary operations in Colombia. We are bullish on SAMA/CLVR and believe in the company's opportunity: the company is early stage, the global cannabis opportunity is significant, and Clever Leaves appears to be positioned for material revenue growth coupled with a very desirable cost structure in 2021 and beyond.
- The leader in low-cost medical-focused cannabis cultivation and extraction
- Thoughtfully constructed, a vertically integrated multinational operator (MNO)
- Pharmaceutical-grade, EU GMP-certified production authorized for export
- Purpose-built for significant growth, profitability, and operating leverage
- Talented and experienced leadership with operational and regulatory expertise
- Attractive valuation.
Kyle Detwiler bio:
- Founded Northern Swan Holdings in 2017, which merged with Clever Leaves in 2019
- Co-founded Silver Swan Capital, an investment firm focused on niche and under-followed sectors Former Principal at Blackstone's Tactical Opportunities Fund
- A former investment professional at KKR focused on the oil and gas, energy, natural resource, and health care sectors
- MBA from Harvard Business School